ChinaBio Today submits:
China Aoxing (CAXG.OB) will collaborate with QRxPharma Limited (QRXPY.PK), a clinical stage Australian pharma, to develop MoxDuo®IV for the China market. MoxDuoIV is an IV formulation of QRxPharma’s patented morphine and oxycodone Dual-Opioid™ technology for the acute treatment of moderate to severe pain.
China Aoxing will fund development of MoxDuo®IV for the China market in exchange for exclusive marketing rights of the product in China. QRxPharma will retain ownership of MoxDuo®IV and may use the clinical work completed by China Aoxing in product registrations outside of China. Further financial details of the collaboration were not disclosed.
Further information:
Related posts:
- China Aoxing Pharmaceutical Company Announce March Investor Conferences Participation
- China Aoxing Pharmaceutical Company Reports Second Quarter 2010 Financial and Operational Results
- QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
- S3 Investment Company Announces Ongoing Work by Redwood Capital Subsidiary for Additional SFDA Approvals for First Product to Be Distributed in China
- S3 Investment Company Comments on New Redwood Capital Subsidiary Client and Its Potential in China’s Cattle Industry
Posted in